--- title: $2.1 Million Award for Cancer Patient’s Bisphosphonate Drug Complications description: Between 1999 and 2005, 62-year-old Adriann Georges took Aredia and Zometa, bisphosphonate drugs used to prevent the loss of bone mass in cancer patients. --- [Skip to content](https://counselfinancial.com/litigation-counsellor/2-1-million-award-for-cancer-patients-bisphosphonate-drug-complications-2/#main-content) [![Brandmark](https://counselfinancial.com/hubfs/2024%20Website/Brand%20Logos/Brandmark.svg "Brandmark")](https://counselfinancial.com/) [![Counsel Financial](https://counselfinancial.com/hubfs/2024%20Website/Brand%20Logos/Text-Logo.svg "Counsel Financial")](https://counselfinancial.com/) - [Law Firms](https://counselfinancial.com/law-firms) - [Capital Providers](https://counselfinancial.com/captial-providers) - About Us Show submenu for About Us ![](https://counselfinancial.com/hubfs/raw_assets/public/Counsel-Financial-Theme/images/icons/arrow-down.svg) - [Loan Process](https://counselfinancial.com/about/loan-process) - [Our Team](https://counselfinancial.com/about/our-team) - [Lending Philosophy](https://counselfinancial.com/about/lending-philosophy) - [Contact](https://counselfinancial.com/contact) - Resources Show submenu for Resources ![](https://counselfinancial.com/hubfs/raw_assets/public/Counsel-Financial-Theme/images/icons/arrow-down.svg) - [Blog](https://counselfinancial.com/blog) - [Case Studies](https://counselfinancial.com/case-studies) - [Law Firms](https://counselfinancial.com/law-firms) - [Capital Providers](https://counselfinancial.com/captial-providers) - About Us Show submenu for About Us ![](https://counselfinancial.com/hubfs/raw_assets/public/Counsel-Financial-Theme/images/icons/arrow-down.svg) - [Loan Process](https://counselfinancial.com/about/loan-process) - [Our Team](https://counselfinancial.com/about/our-team) - [Lending Philosophy](https://counselfinancial.com/about/lending-philosophy) - [Contact](https://counselfinancial.com/contact) - Resources Show submenu for Resources ![](https://counselfinancial.com/hubfs/raw_assets/public/Counsel-Financial-Theme/images/icons/arrow-down.svg) - [Blog](https://counselfinancial.com/blog) - [Case Studies](https://counselfinancial.com/case-studies) [Request a Meeting ![](https://counselfinancial.com/hubfs/raw_assets/public/Counsel-Financial-Theme/images/icons/button-arrow-blue.svg)](https://counselfinancial.com/request-a-meeting) [Contact ![](https://counselfinancial.com/hubfs/raw_assets/public/Counsel-Financial-Theme/images/icons/button-arrow-blue.svg)](https://counselfinancial.com/contact) [Products Liability](https://counselfinancial.com/litigation-counsellor/topic/products-liability), [Litigation Counsellor](https://counselfinancial.com/litigation-counsellor/topic/litigation_counsellor) # $2.1 Million Award for Cancer Patient’s Bisphosphonate Drug Complications By: Kim Gomlak, MBA | Marketing Director August 12, 2013 Between 1999 and 2005, 62-year-old Adriann Georges took Aredia and Zometa, bisphosphonate drugs used to prevent the loss of bone mass in cancer patients. Georges subsequently developed bisphosphonate-associated osteonecrosis of the jaw (ONJ), a severe bone disease that occurs when the jawbone is exposed for eight weeks or more, causing the jawbone to weaken and die. ONJ can be permanently disfiguring, extremely painful and result in the complete loss of an individual’s jawbone. Despite ONJ being linked to bisphosphonate drugs Aredia and Zometa, ONJ was not indicated as a risk on the drugs’ labels.   Georges filed suit against Novartis Pharmaceuticals Corp., the manufacturer of Aredia and Zometa, alleging that Defendant failed to timely warn of the correlation between bisphosphonates and the development of ONJ, intentionally concealed findings of such a correlation and breached the implied warranty of marketability. As a result, Georges developed ONJ after taking the drugs over a period of time, causing pieces of her jawbone to extrude from her face.   At trial, counsel for Plaintiff presented evidence that Defendants were aware of the risk as early as 2002. Despite such knowledge, Defendants developed a program to downplay any relationship between bisphosphonates and ONJ, and discouraged the dissemination of information about the disease.   Counsel for the Defendant presented evidence of other causes of ONJ and argued that prior to 2002 there was no information to suggest that ONJ was a possible consequence of bisphosphonate therapy. Moreover, Defendant claimed it reacted promptly and appropriately to the first reports of complications. Defendant further maintained that the drugs were in fact effective and that the therapeutic benefits outweighed the risks.   The jury returned a verdict in favor of Plaintiff’s claims of failure to warn, negligent manufacturing and intentional concealment and awarded her $2,162,000. *VERDICT:* **$2,162,000** *COURT:* **United States District Court, Central District, Los Angeles, CA**   Counsel Financial provides working capital credit lines up to $5 million exclusively for the plaintiffs' bar. [Explore all of our financial solutions designed for contingent fee practice.](https://attorneylending-1958486.hs-sites.com/contact-us) [Products Liability](https://counselfinancial.com/litigation-counsellor/topic/products-liability), [Litigation Counsellor](https://counselfinancial.com/litigation-counsellor/topic/litigation_counsellor) ## Recent Posts ### [Nursing home negligence causes septicemia which allegedly caused patient's death Learn More ![](https://counselfinancial.com/hubfs/raw_assets/public/Counsel-Financial-Theme/images/theme-assets/link-graphic-green.svg)](https://counselfinancial.com/litigation-counsellor/nursing-home-negligence-causes-septicemia-which-allegedly-caused-patients-death/) ### [Pennsylvania: Nursing home negligence causes septicemia which allegedly caused patient's death Learn More ![](https://counselfinancial.com/hubfs/raw_assets/public/Counsel-Financial-Theme/images/theme-assets/link-graphic-green.svg)](https://counselfinancial.com/litigation-counsellor/pennsylvania-nursing-home-negligence-causes-septicemia-which-allegedly-caused-patients-death/) ### [Over $1 Billion Settlement Reached Between Stryker and Thousands of Hip Implant Patients Learn More ![](https://counselfinancial.com/hubfs/raw_assets/public/Counsel-Financial-Theme/images/theme-assets/link-graphic-green.svg)](https://counselfinancial.com/litigation-counsellor/hip-implant/) ![Counsel Financial](https://counselfinancial.com/hubfs/2024%20Website/Brand%20Logos/Full-Logo-Stacked.svg) ![minimal-brandmark](https://counselfinancial.com/hubfs/2024%20Website/Brand%20Logos/minimal-brandmark.svg) - [![location](https://counselfinancial.com/hubfs/2024%20Website/Icons/location.svg) 500 Pearl St., 
 Suite 820
 Buffalo, NY 14202](https://maps.app.goo.gl/xQVgoc7dvspNBDsy6) - [![phone](https://counselfinancial.com/hubfs/2024%20Website/Icons/phone.svg) (716) 568–0070](tel:+17165680070) Law Firms - [Law Firm Loans](https://counselfinancial.com/law-firms) Capital Providers - [Capital Solutions](https://counselfinancial.com/captial-providers) About Us - [Loan Process](https://counselfinancial.com/about/loan-process) - [Our Team](https://counselfinancial.com/about/our-team) - [Lending Philosophy](https://counselfinancial.com/about/lending-philosophy) - [Contact](https://counselfinancial.com/contact) Resources - [Case Studies](https://counselfinancial.com/case-studies) - [Blog](https://counselfinancial.com/blog) --- © 2026 Counsel Financial  |  [Privacy Policy](https://counselfinancial.com/privacy-policy)  |  [Terms](https://counselfinancial.com/terms-and-conditions-of-use)  |  [Cookie Policy](https://counselfinancial.com/cookie-policy) [Follow us on LinkedIn](https://www.linkedin.com/company/counsel-financial-services/)